Preview

Российский биотерапевтический журнал

Расширенный поиск

АКТУАЛЬНОСТЬ ДАЛЬНЕЙШИХ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ПРИМЕНЕНИЯ МЕЛАТОНИНА В АДЪЮВАНТНОЙ ОНКОТЕРАПИИ

https://doi.org/10.17650/1726-9784-2021-20-1-24-32

Полный текст:

Аннотация

Обзор составлен на основании поиска в PubMed, Web of Science, Scopus и Google, который показал недостаток информации по клиническим исследованиям применения мелатонина (М) в онкологии, несмотря на многочисленные и многообещающие результаты экспериментов. В предварительных клинических исследованиях, выполненных группой P. Lissony, отмечается терапевтический потенциал М в качестве вспомогательного средства при химио‑, лучевой терапии и иммунотерапии опухолей различной локализации. М смягчает токсическое действие стандартной терапии и, по наблюдениям авторов, повышает ее эффективность. Экзогенный М может быть востребован в качестве синхронизатора циркадного ритма для реабилитации и улучшения качества жизни больных, так как уменьшает дистресс и улучшает сон, а также в поддерживающей и паллиативной терапии. Онкостатическая активность М связана с влиянием: на) на гомеостаз и циркадные ритмы, б) воспаление, кооперацию иммуноцитов и продукцию цитокинов в микроокружении опухоли, в) экспрессию генов и сигнальные пути, связанные с ангиогенезом, пролиферацией и метастазированием, г) метаболизм, гипоксию и оксидативный стресс, д) апоптоз и резистентность к химио‑ и лучевой терапии. Обзор содержит следующие разделы: физиологические и фармакологические исследования, эпидемиологические исследования, клинические исследования, иммунорегуляторная роль М, экспериментальные исследования. В настоящее время востребованы рандомизированные и длительные клинические исследования гомогенных групп больных со II−III стадиями рака для статистической обработки информации по влиянию М на побочное действие стандартной терапии, динамику болезни, клинические параметры, а также на качество и продолжительность жизни после основного лечения.

Об авторе

Е. П. Смородин
Департамент вирологии и иммунологии, Национальный институт развития здоровья
Эстония

Евгений Павлович Смородин  

Эстония, 11619 Таллинн, Хийу, 42



Список литературы

1. Posadzki P.P., Bajpai R., Kyaw B.M. et al. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Med 2018;16(1):18. DOI: 10.1186/s12916- 017-1000-8. PMID: 29397794.

2. Reiter R.J., Rosales-Corral S.A., Tan D.X. et al. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci 2017;18(4):843. DOI: 10.3390/ijms18040843. PMID: 28420185.

3. Gooneratne N.S., Edwards A.Y., Zhou C. et al. Melatonin pharmacokinetics following two different oral surgesustained release doses in older adults. J Pineal Res 2012;52(4):437–45. DOI: 10.1111/j.1600-079X.2011.00958.x. PMID: 22348451.

4. Esteban-Zubero E., López-Pingarrón L., Alatorre-Jiménez M.A. et al. Melatonin's role as a co-adjuvant treatment in colonic diseases. Life Sci 2017;170:72–81. DOI: 10.1016/j.lfs.2016.11.031. PMID: 27919824.

5. Andersen L.P., Gögenur I., Rosenberg J. The Safety of Melatonin in Humans. Clin Drug Investig 2016;36(3):169–75. DOI: 10.1007/s40261-015-0368-5. PMID: 26692007.

6. Andersen L.P., Werner M.U., Rosenkilde M.M. et al. Pharmacokinetics of highdose intravenous melatonin in humans. J Clin Pharmacol 2016;56(3):324–9. DOI: 10.1002/jcph.592. PMID: 26184078.

7. Besag F.M.C., Vasey M.J., Lao K.S.J. et al. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review. CNS Drugs 2019;33:1167–86. DOI: 10.1007/s40263-019-00680-w. PMID: 31722088.

8. Harpsøe N.G., Andersen L.P., Gögenur I. et al. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol 2015;71(8):901–9. DOI: 10.1007/s00228-015-1873-4. PMID: 26008214.

9. Zetner D., Andersen L.P., Rosenberg J. Pharmacokinetics of alternative administration routes of melatonin: a systematic review. Drug Res (Stuttg) 2016;66(4):169–73. DOI: 10.1055/s-0035-1565083. PMID: 26514093.

10. Giudice A., Crispo A., Grimaldi M. et al. The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis. Molecules 2018;23(6):1308. DOI: 10.3390/molecules23061308. PMID: 29844288.

11. Liu W., Zhou Z., Dong D. et al. Sex Differences in the Association between Night Shift Work and the Risk of Cancers: A Meta-Analysis of 57 Articles. Dis Markers 2018;2018:7925219. DOI: 10.1155/2018/7925219. PMID: 30598709.

12. Li Y., Li S., Zhou Y. et al. Melatonin for the prevention and treatment of cancer. Oncotarget 2017;8(24):39896–921. DOI: 10.18632/oncotarget.16379. PMID: 28415828.

13. Zaki N.F., Sabri Y.M., Farouk O. et al. Depressive Symptoms, Sleep Profiles and Serum Melatonin Levels in a Sample of Breast Cancer Patients. Nat Sci Sleep 2020;12:135–49. DOI: 10.2147/NSS. S206768. PMID: 32104121.

14. Stanciu A.E., Zamfir-Chiru-Anton A., Stanciu M.M. et al. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. Oncol Lett 2020;19(2):1537–43. DOI: 10.3892/ol.2019.11215. PMID: 31966079.

15. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 2007;55(3–4):201–4. DOI: 10.1016/j.patbio.2006.12.025. PMID: 17446010.

16. Lissoni P., Chilelli M., Villa S. et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003;35(1):12–5. DOI: 10.1034/j.1600-079x.2003.00032.x. PMID: 12823608.

17. Lissoni P., Messina G., Lissoni A. et al. The psychoneuroendocrineimmunotherapy of cancer: Historical evolution and clinical results. J Res Med Sci 2017;22:45. DOI: 10.4103/jrms.JRMS_255_16. PMID: 28567065.

18. Neri B., de Leonardis V., Gemelli M.T. et al. Melatonin as biological response modifier in cancer patients. Anticancer Res 1998;18(2B):1329–32. PMID: 9615811.

19. Berk L., Berkey B., Rich T. et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys 2007;68(3):852–7. DOI: 10.1016/j.ijrobp.2007.01.012. PMID: 17418968.

20. Sookprasert A., Johns N.P., Phunmanee A. et al. Melatonin in patients with cancer receiving chemotherapy: a randomized, doubleblind, placebo-controlled trial. Anticancer Res 2014;34(12):7327–37. PMID: 25503168.

21. Seely D., Wu P., Fritz H. et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther 2012;11(4):293–303. DOI: 10.1177/1534735411425484. PMID: 22019490.

22. Wang Y., Wang P., Zheng X., Du X. Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. Onco Targets Ther 2018;11:7895–908. DOI: 10.2147/OTT.S174100. PMID: 30510430.

23. Lissoni P. A reinterpretation of the pathogenesis and cure of cancer according to the psychoneuroimmunological discoveries. Methods Mol Biol 2012;934:183–92. DOI: 10.1007/978-1-62703-071-7_10. PMID: 22933147.

24. Vigoré L., Messina G., Brivio F. et al. Psychoneuroendocrine modulation of regulatory T lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin. In Vivo 2010;24(5):787–9. PMID: 20952751.

25. Lissoni P., Barni S., Tancini G. et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69(1):196–9. DOI: 10.1038/ bjc.1994.34. PMID: 8286206.

26. Lissoni P., Rovelli F., Porro G. et al. Treatment of Advanced Cancer related Lymphocytopenia: Comparison among the Effects of Subcutaneous Low-dose Interleukin-2, High-dose Pineal Hormone Melatonin and Checkpoint Inhibitors. J Cancer Res Oncobiol 2018;1(3):112. DOI: 10.31021/jcro.20181112.

27. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 2000;917:560–7. DOI: 10.1111/j.1749-6632.2000. tb05421.x. PMID: 11268384.

28. Lissoni P., Brivio F., Fumagalli L. et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 2008;28(2B):1377–81. PMID: 18505083.

29. Cerea G., Vaghi M., Ardizzoia A. et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 2003;23(2C):1951–4. PMID: 12820485.

30. Lissoni P., Barni S., Mandalà M. et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35(12):1688–92. DOI: 10.1016/s0959-8049(99)00159-8. PMID: 10674014.

31. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002;10(2):110–6. DOI: 10.1007/s005200100281. PMID: 11862501.

32. Sarma A., Rodriguez M.A., Cabanillas F. et al. A randomized trial of CHOP chemotherapy with or without melatonin in patients with favourable prognosis large B-cell lymphoma. J Clin Oncol 2004;22(14):8066. DOI: 10.1200/jco.2004.22.90140.8066.

33. Ghielmini M., Pagani O., de Jong J. et al. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 1999;80(7):1058–61. DOI: 10.1038/sj.bjc.6690463. PMID: 10362116.

34. Nahleh Z., Pruemer J., Lafollette J., Sweany S. Melatonin, a promising role in taxane-related neuropathy. Clin Med Insights Oncol 2010;4:35–41. DOI: 10.4137/cmo.s4132. PMID: 20567633.

35. Onseng K., Johns N.P., Khuayjarernpanishk T. et al. Beneficial Effects of Adjuvant Melatonin in Minimizing Oral Mucositis Complications in Head and Neck Cancer Patients Receiving Concurrent Chemoradiation. J Altern Complement Med 2017;23(12):957–63. DOI: 10.1089/acm.2017.0081. PMID: 28657801.

36. Khare A., Thada B., Jain N. et al. Comparison of Effects of Oral Melatonin with Oral Alprazolam used as a Premedicant in Adult Patients Undergoing Various Surgical Procedures under General Anesthesia: A Prospective Randomized Placebo-Controlled Study. Anesth Essays Res 2018;12(3):657–62. DOI: 10.4103/aer.AER_90_18. PMID: 30283171.

37. Innominato P.F., Lim A.S., Palesh O. et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer 2016;24(3):1097–105. DOI: 10.1007/s00520-015-2883-6. PMID: 26260726.

38. Palmer A.C.S., Zortea M., Souza A. et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. PLoS One 2020;15(4):e0231379. DOI: 10.1371/journal.pone.0231379. PMID: 32302347.

39. Palmer A.C.S., Souza A., Dos Santos V.S. et al. The Effects of Melatonin on the Descending Pain Inhibitory System and Neural Plasticity Markers in Breast Cancer Patients Receiving Chemotherapy: Randomized, DoubleBlinded, Placebo-Controlled Trial. Front Pharmacol 2019;10:1382. DOI: 10.3389/fphar.2019.01382. PMID: 31824318.

40. Lissoni P., Rovelli F., Frassineti A. et al. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone. Neuro Endocrinol Lett 2000;21(4):319–23. PMID: 11455367.

41. Lissoni P., Messina G., Rovelli F. Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. Curr Aging Sci 2012;5(3):231–5. DOI: 10.2174/1874609811205030010. PMID: 23451999.

42. Lissoni P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris) 2007;55(3–4):198–200. DOI: 10.1016/j.patbio.2006.12.008. PMID: 17451889.

43. Lissoni P., Rovelli F., Brivio F. et al. Five year-survivals with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible for the only palliative therapy. Res J Oncol 2018;2(1):2.

44. Moradkhani F., Moloudizargari M., Fallah M. et al. Immunoregulatory role of melatonin in cancer. J Cell Physiol 2020;235(2):745–57. DOI: 10.1002/jcp.29036. PMID: 31270813.

45. Carrillo-Vico A., Lardone P.J., Alvarez-Sánchez N. Melatonin: buffering the immune system. Int J Mol Sci 2013;14(4):8638–83. DOI: 10.3390/ijms14048638. PMID: 23609496.

46. Hardeland R. Aging, Melatonin, and the pro- and anti-inflammatory networks. Int J Mol Sci 2019;20(5). DOI: 10.3390/ijms20051223. PMID: 30862067.

47. Ren W., Liu G., Chen S. et al. Melatonin signaling in T cells: Functions and applications. J Pineal Res 2017;62(3):10.1111/jpi.12394. DOI: 10.1111/jpi.12394. PMID: 28152213.

48. Guo L., Wang C., Qiu X. et al. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy. Front Immunol 2020;11:1052. DOI: 10.3389/fimmu.2020.01052. PMID: 32547556.

49. Najafi S., Mirshafiey A. The role of T helper 17 and regulatory T cells in tumor microenvironment. Immunopharmacol Immunotoxicol 2019;41(1): 16–24. DOI: 10.1080/08923973. 2019.1566925. PMID: 30714422.

50. Zhuo C., Xu Y., Ying M. et al. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res 2015;61(3):338–47. DOI: 10.1007/s12026-014-8616-y. PMID: 25608795.

51. Mortezaee K., Potes Y., MirtavoosMahyari H. et al. Boosting immune system against cancer by melatonin: A mechanistic viewpoint. Life Sci 2019;238:116960. DOI: 10.1016/j.lfs.2019.116960. PMID: 31629760.

52. Cheng L., Liu J., Liu Q. et al. Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages. Int J Biol Sci 2017;13(6):723–34. DOI: 10.7150/ijbs.19642. PMID: 28655998.

53. Guo Y.H., Sun H.F., Zhang Y.B. et al. The clinical use of the platelet/ lymphocyte ratio and lymphocyte/ monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis. Oncotarget 2017;8(12):20011–24. DOI: 10.18632/oncotarget.15311. PMID: 28212553.

54. Lissoni P., Messina G., Borsotti G. et al. Modulation of Immune and Anti-Tumor Effects of Cancer Immunotherapy With Anti-Pd-1 Monoclonal Antibodies by the Pineal Hormone Melatonin: Preliminary Clinical Results. J Immuno Allerg 2020;1(1):1–6. DOI: 10.37191/ Mapsci-2582-6549-1(1)-005.

55. Jung-Hynes B., Schmit T.L., ReaganShaw S.R. et al. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011;50(2):140–9. DOI: 10.1111/j.1600-079X.2010.00823.x. PMID: 21062352.

56. Paroni R., Terraneo L., Bonomini F. et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. J Pineal Res 2014;57(1):43–52. DOI: 10.1111/jpi.12142. PMID: 24786921.

57. Su S.C., Hsieh M.J., Yang W.E. et al. Cancer metastasis: Mechanisms of inhibition by melatonin. J Pineal Res 2017;62(1):10. DOI: 10.1111/jpi.12370. PMID: 27706852.

58. Ma Q., Reiter R.J., Chen Y. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis 2020;23(2):91– 104. DOI: 10.1007/s10456-019-09689-7. PMID: 31650428.

59. Lo Sardo F., Muti P., Blandino G., Strano S. Melatonin and Hippo Pathway: Is There Existing Cross-Talk? Int J Mol Sci 2017;18(9):1913. DOI: 10.3390/ijms18091913. PMID: 28878191.

60. Li H.R., Wang C., Sun P. et al. Melatonin attenuates doxorubicininduced cardiotoxicity through preservation of YAP expression. J Cell Mol Med 2020;24(6):3634–46. DOI: 10.1111/jcmm.15057. PMID: 32068341.

61. Haghi-Aminjan H., Farhood B., Rahimifard M. et al. The protective role of melatonin in chemotherapy-induced nephrotoxicity: a systematic review of non-clinical studies. Expert Opin Drug Metab Toxicol 2018;14(9):937–50. DOI: 10.1080/17425255.2018.1513492. PMID: 30118646.

62. Najafi M., Hooshangi Shayesteh M.R., Mortezaee K. et al. The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. Life Sci 2020;241:117173. DOI: 10.1016/j.lfs.2019.117173. PMID: 31843530.

63. Ma Z., Xu L., Liu D. et al. Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing. Oxid Med Cell Longev 2020;2020:6841581. DOI: 10.1155/2020/6841581. PMID: 32566095.

64. Farhood B., Goradel N.H., Mortezaee K. et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol 2019;21(3):268–79. DOI: 10.1007/s12094-018-1934-0. PMID: 30136132.

65. Maroufi N.F., Vahedian V., Hemati S. et al. Targeting cancer stem cells by melatonin: Effective therapy for cancer treatment. Pathol Res Pract 2020;216(5):152919. DOI: 10.1016/j.prp.2020.152919. PMID: 32171553.

66. Koçak N., Dönmez H., Yildirim İ.H. Effects of melatonin on apoptosis and cell differentiation in MCF-7 derived cancer stem cells. Cell Mol Biol (Noisy-le-grand) 2018;64(12):56–61. PMID: 30301504.

67. Hu C., Li L. Melatonin plays critical role in mesenchymal stem cell-based regenerative medicine in vitro and in vivo. Stem Cell Res Ther 2019;10(1):13. DOI: 10.1186/s13287-018-1114-8. PMID: 30635065.

68. Vriend J., Reiter R.J. The Keap1-Nrf2- antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endocrinol 2015;401:213–20. DOI: 10.1016/j.mce.2014.12.013. PMID: 25528518

69. Chuffa L., Seiva F., Cucielo M. et al. Clock genes and the role of melatonin in cancer cells: an overview. Melatonin Research 2019;2(2):133-57. DOI: 10.32794/ mr11250026.

70. Zhang J., Lv H., Ji M. et al. Low circadian clock genes expression in cancers: A meta-analysis of its association with clinicopathological features and prognosis. PLoS One 2020;15(5):e0233508. DOI: 10.1371/journal.pone.0233508. PMID: 32437452.

71. Sulli G., Lam M.T.Y., Panda S. Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment. Trends Cancer 2019;5(8):475–94. DOI: 10.1016/j.trecan.2019.07.002. PMID: 31421905.

72. Heudobler D., Lüke F., Vogelhuber M. et al. Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction. Front Oncol 2019;9:1408. DOI: 10.3389/ fonc.2019.01408. PMID: 31921665.

73. Heudobler D., Rechenmacher M., Lüke F. et al. Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Front Pharmacol 2018;9:1357. DOI: 10.3389/fphar.2018.01357. PMID: 30546308.

74. Bondy S.C., Campbell A. Mechanisms Underlying Tumor Suppressive Properties of Melatonin. Int J Mol Sci 2018;19(8):2205. DOI: 10.3390/ijms19082205. PMID: 30060531.

75. Block K.I., Gyllenhaal C., Lowe L. et al. Designing a broadspectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015;35 Suppl(Suppl):S276–S304. DOI: 10.1016/j.semcancer.2015.09.007. PMID: 26590477.


Для цитирования:


Смородин Е.П. АКТУАЛЬНОСТЬ ДАЛЬНЕЙШИХ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ПРИМЕНЕНИЯ МЕЛАТОНИНА В АДЪЮВАНТНОЙ ОНКОТЕРАПИИ. Российский биотерапевтический журнал. 2021;20(1):24-32. https://doi.org/10.17650/1726-9784-2021-20-1-24-32

For citation:


Smorodin Е.Р. RELEVANCE OF FURTHER CLINICAL TRIALS OF THE USE OF MELATONIN IN ADJUVANT CANCER THERAPY. Russian Journal of Biotherapy. 2021;20(1):24-32. (In Russ.) https://doi.org/10.17650/1726-9784-2021-20-1-24-32

Просмотров: 51


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9784 (Print)
ISSN 1726-9792 (Online)